Skip to main content

NEW Kits for Spikeable/Instillable Connections NOW AVAILABLE!

Research

Explore research, articles, and publications featuring Irrisept

Contact a Rep
A researcher examining some papers
Studies

Kinetic Time-Kill Study

Bioscience Labs Inc. (now part of Nelson Labs), an independent testing organization, used the In-Vitro Kinetic Time-Kill Method to evaluate the properties of Irrisept solution containing 0.05% chlorhexidine gluconate (CHG) when challenged with several different microorganism species. CHG acts as a preservative to inhibit microbial growth in the bottled solution. All testing was performed in accordance with Good Laboratory Practices, as specified in FDA 21 CFR Part 58.1

View the Kinetic Time-Kill Study

Safety Studies

Irrisept features an extensive safety profile with in-vitro and in-vivo studies and RCT data, with >12 years of proven history and testing.1-3

Irrisept meets biocompatibility guidelines for ≤ 24 hours contact with breached or compromised surfaces following the ISO standard 10993-1. The following testing supports biocompatibility of Irrisept for the intended use of wound cleansing and debridement:

  • Cytotoxicity
  • Sensitization
  • Irritation
  • Acute Systemic Toxicity
  • Material Mediated Pyrogens

Reports for all testing stated above are on file and available upon request through Irrimax Corporation.

Request Results
Publications

Irrisept is referenced by name and concentration in independent publications.4-11

Request Publications
Research Program

Irrimax Corporation supports research involving Irrimax products to help identify new ways to help treat patients and prevent infections, reduce healthcare costs, and improve patient outcomes and the safety of healthcare professionals.

Irrimax is committed to sharing clinical data with healthcare professionals, patients, policymakers, and the public.

To learn more about our research program, please email us and we will connect you with a clinical team member.

Email
Research Program

Irrimax Corporation supports research involving Irrimax products to help identify new ways to help treat patients and prevent infections, reduce healthcare costs, and improve patient outcomes and the safety of healthcare professionals.

Irrimax is committed to sharing clinical data with healthcare professionals, patients, policymakers, and the public.

To learn more about our research program, please email us and we will connect you with a clinical team member.

Email

References

Skip to content